Search Results
Your search for ,AnD matches 35546 pages
Showing 26101 - 26150
Eduardo Bruera, MD, on Cachexia Assessment and Management State of the Art
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Lorenzo Cohen, MD, on Acupuncture and Other Nondrug Pain Management Techniques
Lorenzo Cohen, MD, of The University of Texas MD Anderson Cancer Center, discusses nonpharmacologic approaches to symptom control. Techniques such as acupuncture for managing pain and chemotherapy-induced nausea and vomiting, or yoga and meditation to help improve quality of life, can be safely...
Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”
Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could help clinicians identify seriously ill patients who would benefit from conversations about their goals and values (Abstract 8).
Anthony L. Back, MD, on Improving Communication Between Patient and Provider
Anthony L. Back, MD, of Seattle Cancer Care Alliance, summarizes a general session on best practices and novel tools for enhancing communication between patients and oncology providers (Abstracts 8,9, 39).
Vicki Jackson, MD, MPH, on Effective Care Integration and the Comanagement Model
Vicki Jackson, MD, MPH, of Massachusetts General Hospital, summarizes her keynote lecture (plenary talk).
Lawrence H. Einhorn, MD, on CINV Clinical Trial Results: The Alliance A221301 Study
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Lawrence H. Einhorn, MD, on Palliative Radiation for Advanced Cancer and Symptomatic Bone Metastases
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the ways in which a dedicated palliative radiation consult service can improve the quality of palliative cancer care (Abstract 110).
Ralph J. Hauke, MD: Toward Improved Quality of Life
Ralph J. Hauke, MD, of Nebraska Cancer Specialists, discusses the application of scientific analysis and research to palliative care issues, which will allow better prognostication, implementation of measures, and improved quality of life.
Betty Ferrell, PhD, RN, on Depression and Cancer Care
Betty Ferrell, PhD, RN, of City of Hope, discusses two papers that look at an important issue from different perspectives: depression and anxiety among family caregivers of patients with advanced cancer, and the link between oncologists’ dispositional affect and depressive symptoms in their...
Jennifer S. Temel, MD's Expert Perspective: Palliative Care in 2015
As Steering Committee Chair of this year’s symposium, Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses the goals and highlights of the meeting.
Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV
Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Judith Paice, PhD, RN, on Neuropathic Pain
Judith Paice, PhD, RN, of Northwestern University, reviews the current principles on assessing and treating neuropathic pain in cancer.
Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers
Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse...
Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline...
Stephen G. Chun, MD, on NSCLC: Results From NRG Oncology/RTOG 0617
Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).
Reshma Jagsi, MD, DPhil, on the Initial Results of the TBCRC 024 Study on Breast Cancer
Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).
Brian D. Kavanagh, MD, on Improving Value and Elevating the Patient Care Experience
Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients...
Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer
Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).
Bruce Minksy, MD's, Expert Perspective: Radiotherapy in 2015
ASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.
Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601
Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).
Anita Mahajan, MD, on Radiotherapy Advances in the CNS and Aerodigestive Tract
Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).
Robert Kuske, MD, on PROMIS Registry Results
Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).
Catherine C. Park, MD, on Novel Clinical Paradigms
Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).
Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).
Bridgett Harr, CNP, on Reducing ER Visits and Admissions in High-Risk Head and Neck Cancer Patients
Bridgett Harr, CNP, of Cleveland Clinic, discusses the advanced practice nurse follow-up clinic, which focuses on symptom management in the first 90 days postchemoradiation (Abstract 3169).
Jay Harris, MD, on Making Sense of Conflicting Data on Breast Irradiation
Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal...
Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Christopher J. Sweeney, MBBS: Testicular Cancer Update
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, and what physicians need to know about the molecular genetics of testicular cancer.
Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
Srikala S. Sridhar, MD: Bladder Cancer Update
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Hans-Joerg Hammers, MD, PhD, on Renal Cancer: Using Immune Checkpoint Blockers in the Clinic
Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 monotherapy and future PD-1 combination therapies for renal cell carcinoma.
Jennifer A. Ligibel, MD, on Breast Cancer Survivorship in Young Women
Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute, discusses the physical activity behaviors and weight changes in a study cohort of young women with breast cancer (Abstract 166).
Lewis E. Foxhall, MD, on Communication and Coordination of Survivorship Care
Lewis E. Foxhall, MD, of The University of Texas MD Anderson Cancer Center, summarizes this session in which presenters covered a range of issues, including the medical home, tools to facilitate communication with cancer survivors, EMRs, reimbursement, and coordinating care with primary care...
Smita Bhatia, MD, MPH, on the Science of Survivorship
Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham, discusses long-term and late effects experienced by cancer survivors.
Christopher J. Recklitis, PhD, MPH, on Fatigue and Sleep Disturbances
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.
Dana Barnea, MD, on Screening Survivors for Thyroid Cancer
Dana Barnea, MD, of Memorial Sloan Kettering Cancer Center, discusses data that suggest annual palpation of the thyroid is an adequate and safe means of screening childhood and young adult cancer survivors, a population at high risk for this type of cancer (Abstract 254).
Erin Elizabeth Hahn, PhD, MPH, on Hodgkin Lymphoma: Post-Treatment Services
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Rachel Lynn Yung, MD, on Weight-Loss Intervention in Obese Survivors
Rachel Lynn Yung, MD, of the Dana-Farber Cancer Institute, discusses her study of a clinic-based intervention for overweight cancer survivors, which resulted in weight loss and improvements in fitness and physical functioning (Abstract 167).
Kerri M. Winters-Stone, PhD, on Peripheral Neuropathy: High Prevalence Among Female Survivors
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative...
Tim A. Ahles, PhD, on Neurocognitive Late Effects
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).
Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Daniel G. Haller, MD, on Colon and Rectal Cancers: A Global Overview
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Patricia A. Ganz, MD, on Looking Beyond the Scans: What to Look For and How
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.
James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
ASCO Praises President’s Sharp Focus on Cancer
ASCO applauds President Obama for his bold vision to launch a national effort on cancer, which he described during his State of the Union address on January 12, 2016. We also join him in recognizing Vice President Biden’s leadership in calling for a “moonshot” that will reduce the cancer-related...
USPSTF Recommendation Confirms Value of Screening Mammography
The recently updated U.S. Preventive Services Task Force (USPSTF) recommendation once again confirmed the value of screening mammography, concluding that the benefit of mammography outweighs the harms of screening in all age groups from age 40 through age 74. It emphasizes that both women and...
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
